Across the country, some states are recirculating failed proposals that would establish state-run prescription medicine importation schemes. Such proposals would allow medicines from foreign countries – medicines that have not undergone stringent review by the U.S. Food and Drug Association (FDA) – into the country.
These dangerous proposals threaten the safety of patients without delivering the savings they promise and would likely come at a high cost to the state. To make matter worse, these proposals would also put a strain on local law enforcement. In fact, the National Sheriffs’ Association has said importation would impact the ability of law enforcement to protect public health.
We know state-run importation schemes simply don’t work. In fact, they have been tried and they have failed.
They have failed because costs to states and cities have far outweighed any potential savings for importation programs. At the same time, there was a lack of interest from consumers in importation due to the delays in delivery and concerns about potentially unsafe drugs.
Here are examples of these importation scheme failures:
- Illinois, Wisconsin, Missouri, Kansas, Vermont and Hawaii: In the mid-2000s, these states tried an importation program with a Canadian contractor of online pharmacies. The program cost $1 million to implement, and less than 5,000 people participated. The program was deemed a failure and terminated after four years.
- Massachusetts: Springfield and Boston created a similar program, which was canceled because participants found greater safety and savings through Medicare Part D.
- The Springfield importation program was terminated in 2006 after three years of low participation largely due to the introduction of the Medicare prescription drug benefit.
- Boston’s importation program was terminated in 2008 after four years because it was unable to attract more than a few dozen participants. As of July 2008, only 16 retirees were participating in the program.
- Minnesota: Similar to the cities in Massachusetts, Minnesota’s importation pilot program was terminated after Medicare Part D showed greater participation and savings.
Further, a recent analysis by Avalere illustrates some of the cost and operational considerations involved in establishing a state importation program. These challenges may be why no U.S. Secretary of Health and Human Services has ever certified an importation program, despite having the authority to do so.
State lawmakers, and federal lawmakers considering similar approaches, should take these importation failures into consideration, and instead focus on real solutions that put patients first and actually address the affordability challenges they’re facing without compromising their safety.
Ensuring rebates and savings are passed on to patients, addressing high out-of-pocket costs and providing information about patient assistance programs are all alternatives that would help patients get the life-saving prescription medicines they need. We remain committed to working with state policymakers, patient advocates and others to help improve the pharmacy counter experience without jeopardizing Americans’ safety
Learn more about the dangers of drug importation and why these proposed schemes won’t work here: PhRMA.org/Importation.
Nick McGee
Nick McGee is deputy vice president, public affairs, at PhRMA focusing on communications strategies and activities for the organization’s advocacy priorities.
Nick McGee
Mass compounding puts patients at risk
Advancing patient care: A look at new medicines approved in 2025
Knockoffs of FDA-approved drugs put patients at risk
PDUFA: Essential to America’s edge in drug development and patient access
Major drug compounder is spending millions on misleading Super Bowl ad
More oversight needed of unapproved medicines that threaten patients’ health
The use of real-world data in drug development
New analysis: Accelerated approval pathway is changing lives in underserved communities
Novel treatments and vaccines approved for U.S. patients in 2023 reach five-year high
What they are saying: Florida Drug Importation Program is Unfeasible and Dangerous
Florida’s importation plan puts patients in danger
The Biopharmaceutical Industry Still Needs Clarity from the FDA on Orange Book Listings
Decentralized clinical trials and the future of drug development
How FDA’s modernization strategy could improve drug development
Setting the record straight on accelerated approval
FDA should remain the authority on the safety and effectiveness of medicines
What you should know about real-world evidence and drug development
Three things to know about the accelerated approval pathway
PDUFA and BsUFA reauthorizations are wins for patients
Word of the Month: Biomarkers and surrogate endpoints
ICYMI: Antimicrobial resistance spotlighted as growing public health threat
Why drug importation is bad for Americans
Ensuring timely reauthorization of PDUFA and BsUFA
The accelerated approval pathway: Helping patients with serious or life-threatening diseases
The importance of timely PDUFA and BsUFA reauthorization
ICYMI: New approvals by the FDA in 2021 offer greater treatment options for patients
Biosimilar User Fee Act (III) Performance Goals Letter will help increase options for patients and promote competition
Meeting Tomorrow: Looking ahead to PDUFA VII
The impact of monoclonal antibodies and COVID-19 recovery
PDUFA VII is critical for future biopharmaceutical innovation and for patients
How strengthening the biosimilar marketplace benefits patients
The FDA Office of Minority Health and Health Equity: Working to advance health equity through diversity in research
2020 FDA approvals show innovation despite COVID-19 pandemic challenges
Nearly 400 cell and gene therapies in development to target a broad range of diseases
PhRMA submits comments on FDA’s proposed rule on drug importation
Drug importation: An old idea that is still a bad idea
ICYMI: 2019 brings innovative medicines to patients
PhRMA comments to Congress on Cures 2.0 call to action
What they’re saying: Safety is top concern for recent drug importation proposal
Guest Post: Using the patient voice to go boldly
IP Explained: How Hatch-Waxman successfully balances affordability and innovation
PhRMA CEO raises concerns with Florida importation proposal, highlights reforms needed to lower costs for patients
Guest post: Hearing from patients on Rare Disease Day
Rare Disease Day: Unmet medical need inspires biopharmaceutical innovation
Look at the facts. Drug importation is dangerous.
Putting 2018 medicine approvals in context
FDA needs best and brightest to advance a new era of medicine with America’s biopharmaceutical companies
Balancing innovation and competition in the biologics marketplace
ICYMI: Wall Street Journal highlights dangers of counterfeit medicines entering the United States through drug importation
New analysis shows that more medicines worldwide are available to U.S. patients
Spending on medicines grew less than one percent in 2017
Rare Disease Day: Unmet need inspires innovation
Innovation comes in many forms, including new and expanded uses of existing medicines
ICYMI: Why 2017 medicine approvals matter
New surveys find payers and providers want more data from biopharmaceutical companies
Supporting opportunities for enhanced competition in the marketplace
VIDEO: PhRMA CEO discusses industry response to opioid crisis on Mornings with Maria
Opportunities to build upon enhanced competition for medicines in the marketplace
Why reauthorization of PDUFA matters
A critical opportunity to prevent prescription drug abuse
Former law enforcement officials raise concerns with drug importation proposals
The risks of counterfeit imported medicines
ICYMI: What the experts are saying about importation
Guest Post: The importance of a modern FDA in drug discovery
How drug importation schemes could increase U.S. law enforcement burdens
Case Study: How one online pharmacy knowingly endangered U.S. consumers
Why drug importation threatens patient safety
Fact Check Friday: The truth about drug importation and patient safety
What you don’t know about importation from Canada
Discovery of counterfeit hepatitis C drug is another example of why importation is bad for patients
Why state drug importation pilot programs don’t work
Importation
FDA
Why state drug importation pilot programs don’t work
Why state drug importation pilot programs don’t work